Evercore ISI Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)
Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...
Teva Pharmaceutical (TEVA) Gets a Buy from Argus Research
Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...
The Lancet2d
Applying the estimand framework to inflammatory bowel disease clinical trials
Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...
Orally Disintegrating Tablet Market Size, Growth & Forecats By 2033
The global orally disintegrating tablet market size was valued at USD 14.76 billion in 2024 and is projected to grow from USD 16.33 billion in 2025 to USD 28.88 billion by 2033, exhibiting a CAGR of 7 ...
Chronic Pain Clinical Trial Pipeline Experiences Momentum: Delveinsight Estimates A Diverse Pipeline Comprising 20+ Companies Working In The Domain
Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...
pharmaphorum5d
FDA starts review of Pfizer, Lilly’s non-opioid painkiller
After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab ... Tanezumab and Regeneron/Teva’s fasinumab are the last survivors in a class ...
Medscape2d
Mark J. Alberts, MD
Mark J. Alberts, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee ...
MM&M6d
Rx Rundown: Merck, Biogen, Pfizer and more
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
pharmaphorum5d
Lilly to buy private biotech Disarm Therapeutics for up to $1.36bn
Eli Lilly is to buy the private biotech Disarm Therapeutics ... NICE has already recommended Teva’s rival Ajovy (fremanezumab) this year, although it has rejected Novartis’ Aimovig (erenumab ...
Le Lézard6d
Lexaria Releases Annual Letter from the CEO
KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...
Lexaria Bioscience Corp.: Lexaria Releases Annual Letter from the CEO
KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provi ...